Insider trading

Period: 120 months Stock: VCYT Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

91 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

91 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

91 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

91 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
91 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
91 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

91 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
21 Sep 2026
Leite John Global Chief Commercial Off
Sold on a plan
$160.60K 4,015 at 40.00
3.1%
Planned (10b5-1)
4 Sep 2026
Febbo Phillip G. Chief Scientific & Med Officer
Sold on a plan 2×
$564.41K 13,110 at 43.05
9.0%
Planned (10b5-1)
4 Sep 2026
McGuire Annie EVP, General Counsel
Sold on a plan 2×
$140.21K 3,254 at 43.09
2.4%
Planned (10b5-1)
4 Jun 2026
Leite John Global Chief Commercial Off
Sold on a plan
$699.73K 13,975 at 50.07
9.6%
Planned (10b5-1)
4 Jun 2026
McGuire Annie EVP, General Counsel
Sold on a plan 2×
$158.04K 3,176 at 49.76
2.3%
Planned (10b5-1)
22 May 2026
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$1.09M 24,000 at 45.40
34.6%
Not planned
6 May 2026
McGuire Annie SVP, General Counsel
Sold on a plan 2×
$398.21K 10,204 at 39.03
6.6%
Planned (10b5-1)
4 Mar 2026
McGuire Annie SVP, General Counsel
Sold on a plan 2×
$236.72K 6,658 at 35.55
6.6%
Planned (10b5-1)
4 Mar 2026
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$185.08K 5,260 at 35.19
4.7%
Planned (10b5-1)
2 Mar 2026
Febbo Phillip G. Chief Scientific & Med Officer
Sold on a plan
$485.43K 13,425 at 36.16
10.3%
Planned (10b5-1)
16 Dec 2025
McGuire Annie SVP, General Counsel
Sold on a plan 2×
$463.20K 10,739 at 43.13
13.7%
Planned (10b5-1)
4 Dec 2025
McGuire Annie SVP, General Counsel
Sold on a plan 2×
$67.26K 1,422 at 47.30
1.8%
Planned (10b5-1)
4 Dec 2025
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$60.72K 1,278 at 47.51
1.5%
Planned (10b5-1)
25 Nov 2025
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$140.40K 2,808 at 50.00
3.2%
Planned (10b5-1)
10 Nov 2025
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$215.98K 5,102 at 42.33
11.6%
Not planned
7 Nov 2025
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$233.93K 5,818 at 40.21
11.7%
Not planned
5 Nov 2025
McGuire Annie SVP, General Counsel
Sold on a plan
$258.64K 6,466 at 40.00
7.2%
Planned (10b5-1)
6 Oct 2025
Febbo Phillip G. Chief Scientific & Med Officer
Sold on a plan
$300.71K 8,349 at 36.02
8.3%
Planned (10b5-1)
1 Oct 2025
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$88.87K 2,539 at 35.00
2.8%
Planned (10b5-1)
1 Oct 2025
McGuire Annie SVP, General Counsel
Sold on a plan
$75.61K 2,160 at 35.00
2.4%
Planned (10b5-1)
19 Sep 2025
McGuire Annie SVP, General Counsel
Sold on a plan
$76.92K 2,283 at 33.69
2.4%
Planned (10b5-1)
4 Jun 2025
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$76.41K 2,809 at 27.20
2.9%
Planned (10b5-1)
7 Mar 2025
Leite John Chief Commercial Officer-CLIA
Sold on a plan 2×
$234.63K 7,411 at 31.66
6.9%
Planned (10b5-1)
4 Mar 2025
Febbo Phillip G. Chief Scientific & Med Officer
Sold on a plan 2×
$268.01K 8,037 at 33.35
8.9%
Planned (10b5-1)
4 Mar 2025
McGuire Annie SVP, General Counsel
Sold on a plan
$38.48K 1,142 at 33.69
1.6%
Planned (10b5-1)
27 Feb 2025
Leite John Chief Commercial Officer-CLIA
Sold at will
$194.44K 5,746 at 33.84
6.8%
Not planned
4 Dec 2024
McGuire Annie SVP, General Counsel
Sold on a plan
$823.18K 18,699 at 44.02
20.4%
Planned (10b5-1)
4 Dec 2024
Febbo Phillip G. Chief Scientific & Med Officer
Sold on a plan
$173.45K 3,934 at 44.09
4.6%
Planned (10b5-1)
3 Dec 2024
Leite John Chief Commercial Officer-CLIA
Sold at will
$45.41K 1,050 at 43.25
1.4%
Not planned
3 Dec 2024
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$41.45K 956 at 43.36
2.3%
Not planned
27 Nov 2024
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$215.83K 5,032 at 42.89
10.6%
Not planned
4 Sep 2024
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$163.16K 5,479 at 29.78
6.7%
Planned (10b5-1)
16 Jul 2024
Leite John Chief Commercial Officer-CLIA
Sold on a plan
$31.93K 1,277 at 25.00
1.5%
Planned (10b5-1)
6 Dec 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$27.65K 1,023 at 27.03
1.5%
1 Dec 2022
Anderson Bonnie H Executive Chairwoman
Sold, plan not stated 2×
$2.26M 80,000 at 28.26
55.2%
Sold half or more
11 Nov 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$58.68 2 at 29.34
0.0%
4 Nov 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$25.58K 1,023 at 25.00
1.5%
8 Aug 2022
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated 2×
$1.23M 45,000 at 27.31
28.6%
5 Aug 2022
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated
$2.13M 76,917 at 27.71
32.8%
5 Aug 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$27.28K 1,028 at 26.54
1.4%
4 Mar 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 3×
$577.78K 23,003 at 25.12
27.3%
7 Dec 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 2×
$246.36K 6,125 at 40.22
11.3%
6 Dec 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 3×
$332.78K 9,232 at 36.05
16.2%
17 Sep 2021
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated
$130.48K 2,600 at 50.18
1.2%
10 Sep 2021
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated
$95.05K 1,900 at 50.03
0.9%
8 Sep 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$46.79K 926 at 50.53
1.8%
7 Sep 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 2×
$633.41K 12,531 at 50.55
19.7%
23 Jun 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$173.91K 4,375 at 39.75
7.8%
4 Jun 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 3×
$314.52K 9,081 at 34.63
14.9%
4 Mar 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 9×
$2.57M 52,015 at 49.36
49.2%
Showing 1–50 of 91. Page 1 of 2 Older →